Kianna Nguyen

Kianna Nguyen

Auto-generated profile, based on publicly available information

Kianna Nguyen

Mayo Clinic Medical Scientist Training Program, Mayo Clinic, Rochester, Minnesota, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Thejus JayakrishnanThejus Jayakrishnan
Thejus Jayakrishnan
SASonikpreet Aulakh
Sonikpreet Aulakh
MBMizba Baksh
Mizba Baksh
KNKianna Nguyen
Kianna Nguyen
MAMeghna Ailawadhi
Meghna Ailawadhi
Sikander AilawadhiSikander Ailawadhi
Sikander Ailawadhi
Background: Concern exists that the clinical trial populations differ from respective cancer populations in terms of their age distribution affecting the generalizability of the results, especially in underrepresented minorities. We hypothesized that the clinical trials that do not report race are likely to suffer from a higher degree of age disparity. Methods: Food and Drug Administration (FDA) drug approvals from July 2007 to June 2019 were reviewed to identify oncology approvals, and trials with age details were selected. The outcomes studied were the weighted mean difference in age between the clinical trial population and real-world population for various cancers, the prevalence of race reporting and association of age and race reporting with each other. Results: Of the 261 trials, race was reported in 223 (85.4%) of the trials, while 38 trials (14.6%) had no mention of race. Race reporting improved minimally over time: 29 (85.3%) in 2007–2010 vs. 49 (80.3%) in 2011–2014 vs. 145 (85.4%) during the period 2015–2019 (p-value = 0.41). Age discrepancy between the clinical trial population and the real-world population was higher for studies that did not report race (mean difference −8.8 years (95% CI −12.6 to −5.0 years)) vs. studies that did report it (mean difference −5.1 years, (95% CI −6.4 to −3.7 years), p-value = 0.04). Conclusion: The study demonstrates that a significant number of clinical trials leading to cancer drug approvals suffer from racial and age disparity when compared to real-world populations, and that the two factors may be interrelated. We recommend continued efforts to recruit diverse populations.

13 May 2017 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
DNDuy T Nguyen
Duy T Nguyen
KNKianna Nguyen
Kianna Nguyen
LZLijun Zheng
Lijun Zheng
JSJoseph Schuller
Joseph Schuller
MZMatthew Zipse
Matthew Zipse
WSWilliam H. Sauer
William H. Sauer

1 August 2023 in Cells
Verified
Journal Article
Open access
PDF file
PFPouria Fattahi
Pouria Fattahi
Jose M. De Hoyos-VegaJose M. De Hoyos-Vega
Jose M. De Hoyos-Vega
JCJong Hoon Choi
Jong Hoon Choi
CDCaden D. Duffy
Caden D. Duffy
Alan M Gonzalez-SuarezAlan M Gonzalez-Suarez
Alan M Gonzalez-Suarez
ARAlexander Revzin
Alexander Revzin
Human pluripotent stem cells (hPSCs) are capable of unlimited proliferation and can undergo differentiation to give rise to cells and tissues of the three primary germ layers. While directing lineage selection of hPSCs has been an active area of research, improving the efficiency of differentiation remains an important objective. In this study, we describe a two-compartment microfluidic device for co-cultivation of adult human hepatocytes and stem cells. Both cell types were cultured in a 3D or spheroid format. Adult hepatocytes remained highly functional in the microfluidic device over the course of 4 weeks and served as a source of instructive paracrine cues to drive hepatic differentiation of stem cells cultured in the neighboring compartment. The differentiation of stem cells was more pronounced in microfluidic co-cultures compared to a standard hepatic differentiation protocol. In addition to improving stem cell differentiation outcomes, the microfluidic co-culture system described here may be used for parsing signals and mechanisms controlling hepatic cell fate.

24 October 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
PRPuru Rattan
Puru Rattan
KNKianna Nguyen
Kianna Nguyen
DPDaniel D. Penrice
Daniel D. Penrice
DPDavide Povero
Davide Povero
DSDouglas A. Simonetto
Douglas A. Simonetto

17 June 2025 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
KNKianna Nguyen
Kianna Nguyen
QCQuang Tuan Che
Quang Tuan Che
NHNguyen Quoc Huynh
Nguyen Quoc Huynh
KGKihak Gwon
Kihak Gwon
Alan M Gonzalez-SuarezAlan M Gonzalez-Suarez
Alan M Gonzalez-Suarez
ARAlexander Revzin
Alexander Revzin
This review describes approaches for encapsulation of pluripotent stem cells, the biomaterials used, strategies for differentiation into hepatocytes and β cells, and the impact of microencapsulation on cellular therapy.

14 August 2026 in Hepatology Communications
Verified
Journal Article
Open access
KNKianna M. Nguyen
Kianna M. Nguyen
LOLaura Ongie
Laura Ongie
PXPeng Xu
Peng Xu
DPDaniel D. Penrice
Daniel D. Penrice
YKYael Kusne
Yael Kusne
AFAlejandro Ferrer
Alejandro Ferrer
Background: Telomeres are repetitive sequences at the end of linear chromosomes that preserve genetic information. Patients with telomere biology disorders (TBDs) are subject to multiorgan manifestations, which include the liver. However, due to the rare nature of the disorder, these manifestations are not fully characterized. Methods: Here, we describe the hepatic manifestations of patients with TBD at a large tertiary center within a specialized TBD clinic; 121 consecutive patients with TBD seen from 2017 to 2024 were included. The median age of the TBD diagnosis was 43 years old, with 60% male. The most common pathogenic/likely pathogenic variant was TERT (25%), followed by RTEL1 (10%) and TERC (7%). Results: Evidence of hepatic involvement in TBD was observed in 60% of patients (73 of 121), as determined by imaging studies or abnormal liver chemistries. Hepatic steatosis was the most prevalent imaging finding (56%), while a cholestatic pattern of liver injury was the predominant laboratory abnormality (73%). Biopsy-proven portosinusoidal vascular disorder was present in 4 patients. Findings of portal hypertension were observed in 25 patients (34%), with decompensation observed in 12 patients (16%). Traditional liver imaging modalities (computer tomography, ultrasound, and MRI) were compared with magnetic resonance elastography in 41 patients. Of these, 7 patients had abnormal magnetic resonance elastography with normal traditional imaging (17%), indicating higher sensitivity of magnetic resonance elastography to detect liver involvement. Conclusions: This study describes the liver manifestations within a cohort of patients with TBD with findings of portosinusoidal vascular disorder and hepatopulmonary syndrome similar to other cohorts and a noted higher prevalence of hepatic steatosis as compared with the general population. Liver stiffness measurements, integrated with imaging and laboratory testing, further improve characterization of hepatic manifestations in TBD.